---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-008642"
form_type: "8-K"
ticker: "VYNE"
cik: "0001566044"
company_name: "VYNE Therapeutics Inc."
filed_at: "2026-01-30T23:59:59+00:00"
generated_at: "2026-05-16T05:58:00.367645+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# VYNE amends merger with Yarrow to allow pre-funded warrants and beneficial ownership cap

## Summary
- Amendment allows pre-funded warrants for Yarrow stockholders exceeding 9.99% beneficial ownership limit.
- Parent Pre-Closing Dividend will also be paid to holders of VYNE warrants, per their terms.
- Beneficial ownership limitation per holder set at 0%-19.99%, default 9.99%.
- Amendment signed Jan 30, 2026; merger originally announced Dec 17, 2025.

## SEC filing metadata
- accession: 0001104659-26-008642
- form_type: 8-K
- ticker: VYNE
- cik: 0001566044
- company_name: VYNE Therapeutics Inc.
- filed_at: 2026-01-30T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1566044/000110465926008642/0001104659-26-008642-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1566044/000110465926008642/tm264541d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-008642
- JSON: https://secwatch.observer/filing/0001104659-26-008642.json
- Plain text: https://secwatch.observer/filing/0001104659-26-008642.txt

## Key facts
- Material Agreements
  VYNE Therapeutics Inc. amended Amendment to Agreement and Plan of Merger and Reorganization with Yarrow Merger Sub Corp. and Yarrow Bioscience, Inc. (effective 2026-01-30).
  - Action: amendment
  - Agreement: merger
  - Counterparty: Yarrow Merger Sub Corp. and Yarrow Bioscience, Inc.
  - Effective: 2026-01-30
  source text: On January 30, 2026, VYNE Therapeutics Inc., a Delaware corporation (“VYNE”), Yarrow Merger Sub Corp., a Delaware corporation and a wholly-owned subsidiary of VYNE (“Merger Sub”), and Yarrow Bioscience, Inc., a Delaware corporation (“Yarrow”), entered into an amendment (the “Amendment”) to that certain Agreement and Plan of Merger and Reorganization, dated December 17, 2025 (as amended, the “Merger Agreement”), by and among VYNE, Merger Sub and Yarrow.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1566044/000110465926008642/0001104659-26-008642-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.